These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2026 related articles for article (PubMed ID: 24177375)

  • 1. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
    Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
    Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
    Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease.
    Rimola J; Rodriguez S; García-Bosch O; Ordás I; Ayala E; Aceituno M; Pellisé M; Ayuso C; Ricart E; Donoso L; Panés J
    Gut; 2009 Aug; 58(8):1113-20. PubMed ID: 19136510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation.
    Coimbra AJ; Rimola J; O'Byrne S; Lu TT; Bengtsson T; de Crespigny A; Luca D; Rutgeerts P; Bruining DH; Fidler JL; Sandborn WJ; Santillan CS; Higgins PD; Al-Hawary MM; Vermeire S; Vanbeckevoort D; Vanslembrouck R; Peyrin-Biroulet L; Laurent V; Herrmann KA; Panes J
    Aliment Pharmacol Ther; 2016 Jan; 43(1):61-72. PubMed ID: 26548868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease.
    Alfaro I; Masamunt MC; Planell N; López-García A; Castro J; Gallego M; Barastegui R; Giner A; Vara A; Salas A; Ricart E; Panés J; Ordás I
    World J Gastroenterol; 2019 Apr; 25(14):1764-1774. PubMed ID: 31011260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.
    Rutgeerts P; Reinisch W; Colombel JF; Sandborn WJ; D'Haens G; Petersson J; Zhou Q; Iezzi A; Thakkar RB
    Gastrointest Endosc; 2016 Jan; 83(1):188-97.e1-3. PubMed ID: 26234693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease.
    Ordás I; Rimola J; Alfaro I; Rodríguez S; Castro-Poceiro J; Ramírez-Morros A; Gallego M; Giner À; Barastegui R; Fernández-Clotet A; Masamunt M; Ricart E; Panés J
    Gastroenterology; 2019 Aug; 157(2):432-439.e1. PubMed ID: 30953614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance enterography, colonoscopy, and fecal calprotectin correlate in colonic Crohn's disease.
    Somwaru AS; Khanijow V; Katabathina VS
    BMC Gastroenterol; 2019 Dec; 19(1):210. PubMed ID: 31805875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing pediatric ileocolonic Crohn's disease activity based on global MR enterography scores.
    Pomerri F; Al Bunni F; Zuliani M; Guariso G; Gasparetto M; Giorgi B; Cananzi M; Muzzio PC
    Eur Radiol; 2017 Mar; 27(3):1044-1051. PubMed ID: 27277259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
    Rimola J; Fernàndez-Clotet A; Capozzi N; Rojas-Farreras S; Alfaro I; Rodríguez S; Masamunt MC; Ricart E; Ordás I; Panés J
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1563-1573. PubMed ID: 32886809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline Wall Thickness Is Lower in Mucosa-Healed Segments 1 Year After Infliximab in Pediatric Crohn Disease Patients.
    Kang B; Choi SY; Chi S; Lim Y; Jeon TY; Choe YH
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):279-285. PubMed ID: 27050057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple Enterographic Activity Score for Crohn's Disease: comparison with endoscopic, biochemical, and clinical findings.
    Eder P; Katulska K; Lykowska-Szuber L; Stawczyk-Eder K; Krela-Kaźmierczak I; Linke K
    Pol Arch Med Wewn; 2013; 123(7-8):378-85. PubMed ID: 23778300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance Index of Activity (MaRIA) is reliable in assessing response to treatment in patients with Crohn's disease (CD).
    Zhang YN; Liu YB; Xu J; Cao KM; Zhang XX; Wang YB; Liu F; Duan BS; Hu YD; Chu SG
    Clin Radiol; 2024 Mar; 79(3):230-236. PubMed ID: 38092646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
    Colombel JF; Sandborn WJ; Allez M; Dupas JL; Dewit O; D'Haens G; Bouhnik Y; Parker G; Pierre-Louis B; Hébuterne X
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):423-31.e1. PubMed ID: 24184736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 102.